These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 23623830)

  • 21. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Martin LP; Sill M; Shahin MS; Powell M; DiSilvestro P; Landrum LM; Gaillard SL; Goodheart MJ; Hoffman J; Schilder RJ
    Gynecol Oncol; 2014 Mar; 132(3):526-30. PubMed ID: 24361733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
    Martin JY; Urban RR; Liao JB; Goff BA
    J Gynecol Oncol; 2016 Sep; 27(5):e47. PubMed ID: 27329195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
    Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
    Oza AM; Selle F; Davidenko I; Korach J; Mendiola C; Pautier P; Chmielowska E; Bamias A; DeCensi A; Zvirbule Z; González-Martín A; Hegg R; Joly F; Zamagni C; Gadducci A; Martin N; Robb S; Colombo N
    Int J Gynecol Cancer; 2017 Jan; 27(1):50-58. PubMed ID: 27749456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
    Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
    Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
    Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
    Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
    Fuh KC; Secord AA; Bevis KS; Huh W; ElNaggar A; Blansit K; Previs R; Tillmanns T; Kapp DS; Chan JK
    Gynecol Oncol; 2015 Dec; 139(3):413-8. PubMed ID: 26144600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.
    Liu Y; Ren Z; Xu S; Bai H; Ma N; Wang F
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):645-51. PubMed ID: 25599660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
    Reyners AKL; de Munck L; Erdkamp FLG; Smit WM; Hoekman K; Lalisang RI; de Graaf H; Wymenga ANM; Polee M; Hollema H; van Vugt MATM; Schaapveld M; Willemse PHB;
    Ann Oncol; 2012 Nov; 23(11):2896-2902. PubMed ID: 22689176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
    Asmane I; Kurtz JE; Bajard A; Guastalla JP; Meeus P; Tredan O; Labidi Galy I; Moullet I; Ardisson P; Vincent L; Coeffic D; Dufresne A; Bergerat JP; Ray-Coquard I
    Bull Cancer; 2011 Oct; 98(9):80-9. PubMed ID: 21926034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
    J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.
    Zhao M; Pan X; Layman R; Lustberg MB; Mrozek E; Macrae ER; Wesolowski R; Carothers S; Puhalla S; Shapiro CL; Ramaswamy B
    Invest New Drugs; 2014 Dec; 32(6):1285-94. PubMed ID: 24894652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
    Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
    Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer.
    Cohen S; Schwartz M; Dottino P; Beddoe AM
    J Ovarian Res; 2019 Apr; 12(1):36. PubMed ID: 31027500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
    Cowan M; Swetzig WM; Adorno-Cruz V; Pineda MJ; Neubauer NL; Berry E; Lurain JR; Shahabi S; Taiym D; Nelson V; O'Shea KL; Kocherginsky M; Matei D
    Gynecol Oncol; 2021 Oct; 163(1):57-63. PubMed ID: 34419285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Monk BJ; Sill MW; Walker JL; Darus CJ; Sutton G; Tewari KS; Martin LP; Schilder JM; Coleman RL; Balkissoon J; Aghajanian C
    J Clin Oncol; 2016 Jul; 34(19):2279-86. PubMed ID: 27217446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
    Arimoto T; Nakagawa S; Oda K; Kawana K; Yasugi T; Taketani Y
    Med Oncol; 2012 Jun; 29(2):1253-4. PubMed ID: 21380784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.